{"name":"Chase Therapeutics Corporation","slug":"chase-therapeutics-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CTC-501","genericName":"CTC-501","slug":"ctc-501","indication":"Relapsed or refractory acute myeloid leukemia (AML)","status":"phase_2"}]}],"pipeline":[{"name":"CTC-501","genericName":"CTC-501","slug":"ctc-501","phase":"phase_2","mechanism":"CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells.","indications":["Relapsed or refractory acute myeloid leukemia (AML)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQano1U1ZTRlA5WmNQcGt2bklCbktwQTlvUXpfUmk5UThUWTVKaGNvWTFZenUwMXVVS2I3UHU3ODVXd19QcndOTUpjbWR5NkNiZTBqVndhU0VWTkw4VnpXckVfZUJ0djAzdTlqcTQwd0k1UmEtQWQxQ2ZJRnNyUGZaUWlXcnFKTDNBVHl2SHRzcFR1YjhDeVdJbjZMa0pLX0Z2b0gyVnZQZFNuTDdTbFpQbzhfcGl4TTViV2c4ODgxUmpEYkNKMTNfajI4SkJUVzl0VUlrSFJrWnBMZmVpblJMQjBvZw?oc=5","date":"2026-04-01","type":"pipeline","source":"MarketBeat","summary":"JPMorgan Chase & Co. Sells 186,539 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat","headline":"JPMorgan Chase & Co. Sells 186,539 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOZDlrZEQ5c1NTMUhnVlVQa2JDYWNCcXlmdmtUSGxFaWVhSlhuakZWc3VidUp4elZGQWJpX0t6TThfWF9jRVpfbk5BeVRmZEdiX2RnVzBSd2hieUkzaFR3cWtOckY3MFZ5TkJfT0hsSS14d1M4MjNzNUF1cFBZS3N3WENTX0k4YmtUTGdNOW9SNXdTeS1YeXpVc1pPM19wTVJIY3VrZWVnYW9oX3hyX1psMXMwU0FtT3p2YVJLQWRTSTZlX0tsSHJoVzhzM2EwRjZNcDRfZWRwMlF6NW1J?oc=5","date":"2026-03-31","type":"pipeline","source":"MarketBeat","summary":"JPMorgan Chase & Co. Has $7.72 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat","headline":"JPMorgan Chase & Co. Has $7.72 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQRm5jMUJpQnk1emZwNnB0RmVfb2MzM1RDRHdXbEtfYXhQUWhJaGt5STZKd0oxZnkzWHV3OE9Yc2M0Z0FZbk9nS1NXZ3pYdFFtR09LMHhqdGtWSnEwdUxORjlVT0tQZy1NVTB0NVVwVm5zcjg3ekVXRWZUVEdDVkx3T29UMGpfcHFYeUdNR095RDN3UG1BSVBXcXEyLVRIeWVadzU4bnZJTzNwOEhkRUJEb2RUcFhqVnQyUFJTQlF5WVVEWnJUTzMtaHZZSFo?oc=5","date":"2026-03-31","type":"pipeline","source":"MarketBeat","summary":"JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat","headline":"JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1PUkdIRUNHaWhlbFp5WEwtaWhMdWF4end0WldaSEVlV3p1RlhFZjhVdXN2bWt3WmthQlZuQ29lMlVLVG0teng1TFo1MmJFNG5ERHlr?oc=5","date":"2026-02-25","type":"pipeline","source":"FirstWord Pharma","summary":"Sarepta CEO Doug Ingram to retire by year-end - FirstWord Pharma","headline":"Sarepta CEO Doug Ingram to retire by year-end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdWFtRkRhSHVtWmIwbFRiZEszUjFRWDZ6dk5FN0c2NzhiQWlKb0hlcDNQdGFZWXE5dWExU0VCeVJnNHMyS05VSjI4ZDkzWWZtZEdwaW5reGdTLUFEMlB5U2lhNDdRVy1HbWY2c2pSckFqX0o1M3IzMFEtYm1SSzNVUWxFWkZGZ09nUDN1RUtpY2VLa3JjUl9xVWo3X2Vab0d3SUdmdm4welkxQU41cmlzQWZn?oc=5","date":"2026-01-09","type":"deal","source":"Bloomberg.com","summary":"Pharma Deals on the Rise as Industry Shakes Off Trump Anxiety - Bloomberg.com","headline":"Pharma Deals on the Rise as Industry Shakes Off Trump Anxiety","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOYjBJUmtUeG5nWTFtUzI0ZC0yc1VUQ1dQZXF1UG1zWER3Q2YxY0xiMUNFM0g5bTJPS1VOb2ItZ0R3UWF0YXhzcFlCOU5sQ2dibVIwZFRQdU1xcVNOZ05EZWU0VnJmNHI2SXJwXzhxd29FSG9GY0JDODhIZEhXRWExV3RWVjF4TUVsOXJfd2JITFZldVFIUlg0a2RuTWkxNVg1QTVkbHdDUWd4LUdyS3A3cHR0bnRmQmR5WVozVmJYa1lxbjA1azZnUmlBaEJ5MXAxSTVNajV3eW1QNU4wZjRKUEpTV25SUQ?oc=5","date":"2025-12-15","type":"pipeline","source":"marketscreener.com","summary":"JPMorgan Chase & Co's long position in H-shares of Jiangsu Hengrui Pharmaceuticals increases to 8.29%, HKEX says - marketscreener.com","headline":"JPMorgan Chase & Co's long position in H-shares of Jiangsu Hengrui Pharmaceuticals increases to 8.29%, HKEX says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNVjdXdHh1RkloUmMxRE9Bam1jME15c2dEYTBMeXpNWHU5OWhJd0NsUVdzOVZCdDNob2kwV3lxR3lXSFZRUHlWZXB4UGp4QVVnRUlFRzhCRzFpcnVQU3RjcUM5dTBEaF9vTkZjaUZ2bXhCVjR1bUxZOV9mTmYzZGtBUlhvUzIxVFhlZUxNUjQ0YzVUV211MHEzaWQwTmI?oc=5","date":"2025-10-20","type":"pipeline","source":"BioPharma Dive","summary":"Alto shares double on plans to speed depression drug’s development - BioPharma Dive","headline":"Alto shares double on plans to speed depression drug’s development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQb0pvNnJ3aXNZNl9MSHNnZFhnNkN4V1NMQUNBc3VSOEF2Zmx3cVlrVlZQNXRlRGVOSnpDMVVhd2VqUTh2a2lYa3FIaHJzckVuMHc4ZUgzWWdWdUZKb09zMzh4T0M1NXVuSjVlVGRVSE5sSDR5TE5OTUFYaXZxU094M0NBOW4wZw?oc=5","date":"2025-10-01","type":"deal","source":"The Business Journals","summary":"California company swoops in with $750M to buy Boston biotech - The Business Journals","headline":"California company swoops in with $750M to buy Boston biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPR2JfMlo2LUthMFFESW0zOE5LWERZUTZqNmpJd2prcm9rV0FYVEliWjVXY1ZLUXhZTTg5RmF0SmxWbXVhSTgtbTRFY2VQLThsS3ltZ3pyenl0T3pJaGhma1ZoWGRFaUVYZDRnYjNqTzhyWnlKWDExY0puM2JMemdOdmUzdDBaVzlzQ1B0ZDhVNTVBcEJsM2JEYktSR2EwbVZVSVdTMExIdFF2QzlkSlRVX0gtRE9MNFdBT1diNWhKd3A3blpUOHpISnFWYldjckE5T2NQcXlDSkNIc2NjNlhnWm9Kd0ZVck4tanZQZVNPRXFJZDU0a3VHN1gzVlVnLVc4Q1YzRzVNb3g?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire","headline":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wbHkzV3dGRHNlUDFaUUxYYnN6dG1tcGRkNi1oanEyR0JFeHAwaUlmSDNKNXdUcE0zMWdPNFBPc1N0Wm5ITGo5YlluVlV4MkloT2pr?oc=5","date":"2025-06-03","type":"trial","source":"FirstWord Pharma","summary":"Alto adds resistant depression asset following drug trial flop - FirstWord Pharma","headline":"Alto adds resistant depression asset following drug trial flop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQWGsyellyVnZOVG9JeEhFVXVxTHM0eDd6em5kaXFtRjFFX085MVhyTUYtOG5JNU9FSGFHbWRPaEZXczBVeFhUUWNUMklXUVVScFdVVmQwaDdFYmh1aXE5bFlLSTdyUkt1amNxNUpZbzdtY2FTVGloX3g2SVNBQVlCWXVZS09sYmJudFNrNTJkMVlZLXAt?oc=5","date":"2025-06-03","type":"deal","source":"Yahoo Finance","summary":"Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal - Yahoo Finance","headline":"Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQMDF0WThvc1hZdHNoakJoekVhOURuLUltdURwSFdEMjJJMDI0aGlEQTVVRGVack4xNmVjNFlDS3dJMUZIZzZhX0lhbTdkZ2VlVk5GNl8tY1QxM3lUNzRxX191OUp4R1huOExQNm9oc3JaeUpZU2RNQTJpMnVDN2t1M2t5cDhuczlObXVmdW5raXZxVERSMkN5OTBoMFY5VGdidTNveW5WQmJ6M3BJeXlXWjF3MmxYVTlZMmtrQzJQMWstdExpd2dvZkVZcGJPaXhCeldRNzJPVWpwTEp6ZE9UcVkzMW1HNHhtWmE0MVZLRkFJdE5qci1ndHJtUQ?oc=5","date":"2016-11-22","type":"deal","source":"prnewswire.com","summary":"Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease - prnewswire.com","headline":"Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}